The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Orally effective therapeutics for plaque psoriasis with improved response rates, lower toxicity and costs are needed in clinical practices. This study aims to assess the efficacy and safety of the recently approved TYK2 inhibitor deucravacitinib in adults with moderate to severe plaque p...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Jingyue, Liu, Jiakuo, Liu, Wenwen, Lin, Fei, Shi, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570425/
https://www.ncbi.nlm.nih.gov/pubmed/37841017
http://dx.doi.org/10.3389/fmed.2023.1264667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570425/
https://www.ncbi.nlm.nih.gov/pubmed/37841017
http://dx.doi.org/10.3389/fmed.2023.1264667

Ejemplares similares